by John Conrad | May 28, 2024 | Member News
MAIA Biotechnology, a cutting-edge biopharmaceutical company, is pioneering a novel approach to cancer treatment that could revolutionize the field of oncology. Their premier drug candidate, THIO, is a first-in-class telomere-targeting agent designed to selectively...
